ABBOTT REPORTS FIRST-QUARTER 2021 RESULTS

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Algemeen advies 20/04/2021 15:02
- Sales growth of 35.3 percent; organic sales growth of 32.9 percent
- GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent
- All four major businesses achieved strong sales growth in the quarter
- Projected full-year EPS remains unchanged; reflects growth of more than 35 percent.

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2021.

First-quarter sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis, which excludes the impact of foreign exchange.
First-quarter GAAP diluted EPS was $1.00 and adjusted diluted EPS, which excludes specified items, was $1.32, reflecting 103.1 percent growth versus the prior year.1
Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of at least $3.74. Projected full-year adjusted diluted EPS from continuing operations of at least $5.00 remains unchanged and reflects growth of more than 35 percent versus the prior year.2
Global COVID-19 testing-related sales were $2.2 billion in the first quarter, led by combined sales of $1.8 billion from Abbott's BinaxNOW™, Panbio™ and ID NOW™ rapid testing platforms.
First-quarter sales increased 7.6 percent on a reported basis and 5.7 percent on an organic basis, excluding COVID-19 testing-related sales.
In January, the U.S. Centers for Medicare & Medicaid Services expanded reimbursement coverage eligibility for Abbott's revolutionary MitraClip™ device, which significantly increases the number of people who can benefit from this market-leading, minimally invasive heart device.
In March, Abbott announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed.
In April, Abbott announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) of its BinaxNOW COVID-19 Ag Self Test for individuals with or without symptoms and without the need of a prescription.
"We're off to a very strong start to the year, with all four of our major businesses achieving strong growth," said Robert B. Ford, president and chief executive officer, Abbott. "We're particularly pleased with the growing momentum of several recently launched products and continue to forecast more than 35 percent EPS growth for the year."

FIRST-QUARTER BUSINESS OVERVIEW
Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.

Following are sales by business segment and commentary for the first quarter 2021:

Total Company ($ in millions)
% Change vs. 1Q20
Sales 1Q21 Reported Organic
U.S. Int'l Total U.S. Int'l Total U.S. Int'l Total

Total * 3,838 6,618 10,456 34.4 35.9 35.3 34.4 32.0 32.9
Nutrition 836 1,200 2,036 3.0 9.8 6.9 3.0 9.0 6.4
Diagnostics 1,641 2,373 4,014 104.4 131.9 119.8 104.4 122.9 114.8
Established Pharmaceuticals -- 1,070 1,070 n/a 2.5 2.5 n/a 6.2 6.2

Medical Devices 1,351 1,969 3,320 9.6 15.6 13.1 9.6 8.2 8.8

* Total Q1 2021 Abbott sales from continuing operations include Other Sales of approximately $16 million.

n/a = Not Applicable.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate,
by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year
foreign exchange rates.

First-quarter 2021 worldwide sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis.

Nutrition
($ in millions)
see & read more on
https://abbott.mediaroom.com/2021-04-20-Abbott-Reports-First-Quarter-2021-Results



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL